FS Development Corp. II (FSII) News
Filter FSII News Items
FSII News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FSII News Highlights
- FSII's 30 day story count now stands at 8.
- Over the past 26 days, the trend for FSII's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- PBI and DRUG are the most mentioned tickers in articles about FSII.
Latest FSII News From Around the Web
Below are the latest news stories about FS Development Corp II that investors may wish to consider to help them evaluate FSII as an investment opportunity.
Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19Pardes Biosciences Main Protease Pardes Biosciences Main Protease PBI-0451 Pardes Biosciences PBI-0451 Oral Antiviral Pill Pardes NASDAQ Listing Pardes Biosciences Debuts on NASDAQ PRDS Nasdaq Listed Pardes Biosciences debuts on NASDAQ under ticker symbol "PRDS" Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million, combining approximately $199 million of fund |
Startup with potential Covid-fighting pill eyes $300M SPAC dealThe small company, formed as the Covid pandemic started to take hold in February 2020, could take its oral drug into a late-stage clinical trial as early as the first half of next year. |
FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 InfectionsSAN FRANCISCO & LARKSPUR, Calif., December 21, 2021--FSII and Pardes Biosciences move towards merger with the goal of tackling COVID-19 via an oral antiviral. |
FS Development Corp. II (NASDAQ:FSII) Stock Passes Above 200 Day Moving Average of $0.00Shares of FS Development Corp. II (NASDAQ:FSII) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $10.79. FS Development Corp. II shares last traded at $10.79, with a volume of 169,882 shares changing hands. The businesss 50 day moving [] |
FS Development Corp. II (NASDAQ:FSII) Share Price Crosses Above Two Hundred Day Moving Average of $0.00FS Development Corp. II (NASDAQ:FSII)s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $10.79. FS Development Corp. II shares last traded at $10.79, with a volume of 169,882 shares changing hands. The stocks 50 day simple [] |
FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021LARKSPUR, Calif.--(BUSINESS WIRE)--FS Development Corp. II announces effectiveness of registration statement for proposed business combination with Pardes |
FS Development Corp. II (NASDAQ:FSII) Sees Large Growth in Short InterestFS Development Corp. II (NASDAQ:FSII) was the target of a large growth in short interest in October. As of October 15th, there was short interest totalling 21,400 shares, a growth of 42.7% from the September 30th total of 15,000 shares. Based on an average trading volume of 65,500 shares, the days-to-cover ratio is presently 0.3 [] |
Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 InfectionsCARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which is being developed as a potential oral direct-acting antiviral to treat and prevent infections with SARS-CoV-2, the virus that causes COVID-19. PBI-0451 works by inhibiting Viral Main Protease (Mpro), a highly conserved key protein in the virus required for its r |
Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of DirectorsCARLSBAD, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, today announced the appointments of Deborah M. Autor and Laura J. Hamill to its Board of Directors. “I am thrilled to welcome Deb and Laura to our Board. Both bring extensive and unique industry experience to Pardes, as we prepare for the next stage in our company’s |
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of FS Development Corp. II (Nasdaq - FSII)BALA CYNWYD, PA / ACCESSWIRE / June 29, 2021 / Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of FS Development Corp. ("FSII" or the "Company") (Nasdaq:FSII) for possible breaches of fiduciary duty and other violations of federal and state law in connection with a merger agreement pursuant to which FSII, a special purpose acquisition company, will combine withPardes Biosciences, Inc. |